The proteasome - an intracellular protease that is dysregulated in lung diseases

S. Meiners (München, Germany)

Source: International Congress 2018 – Proteases: at the cutting edge of lung disease
Session: Proteases: at the cutting edge of lung disease
Session type: Symposium
Number: 3541

WebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Meiners (München, Germany). The proteasome - an intracellular protease that is dysregulated in lung diseases. International Congress 2018 – Proteases: at the cutting edge of lung disease

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Lysosomal cysteine proteases in the lung: role in protein processing and immunoregulation
Source: Eur Respir J 2004; 23: 620-628
Year: 2004



Decreased levels of elafin in the lungs of patients with acute lung injury as a result of proteolytic cleavage by the proteasome
Source: Annual Congress 2012 - Mechanistic studies in airway cell biology
Year: 2012

MMPs are regulatory enzymes in pathways of inflammatory disorders, tissue injury, malignancies and remodelling of the lung
Source: Eur Respir J 2011; 37: 12-14
Year: 2011


Composition of the cellular matrix, nutrition, and hypoxia modulate the secretion and activation of collagenases and their inhibitors in human lung cells
Source: Eur Respir J 2001; 18: Suppl. 33, 244s
Year: 2001

ONX0912, a novel proteasome inhibitor for the treatment of lung fibrosis?
Source: Annual Congress 2012 - New drug targets and pre-clinical models for respiratory diseases
Year: 2012

SerpinB1 in cystic fibrosis airway fluids: quantity, molecular form and mechanism of elastase inhibition
Source: Eur Respir J 2011; 37: 1083-1090
Year: 2011



Increased detection of interleukin-;5 in sputum by addition of protease inhibitors
Source: Eur Respir J 2001; 18: 685-691
Year: 2001



Genetic deletion of SLPI promotes inflammatory cell recruitment in a model of chronic lung disease
Source: Virtual Congress 2021 – Emerging new mechanisms of chronic lung disease
Year: 2021


Treatment with proteinase inhibitor, BbCI, modulates inflammatory response, mechanic alterations, and remodeling on elastase-induced emphysema in mice
Source: Annual Congress 2012 - The many roads to lung injury
Year: 2012

A functional variant of secretory leukocyte protease inhibitor (SLPI) with improved anti-inflammatory activity against pulmonary infection
Source: Lung Science Conference 2015
Year: 2015

A therapeutic role for matrix metalloproteinase inhibitors in lung diseases?
Source: Eur Respir J 2011; 38: 1200-1214
Year: 2011



In vivo pharmacological profile of PKF242-484 and PKF241-466, novel dual inhibitors of TNF-α converting enzyme and matrix metalloproteinases, in models of airway inflammation
Source: Eur Respir J 2002; 20: Suppl. 38, 169s
Year: 2002

Airway sphingomyelinase, ceramide pathway and apoptosis in lung disease
Source: Eur Respir J 2005; 26: Suppl. 49, 20s
Year: 2005

Cathepsins in bleomycin-induced lung injury in rat
Source: Eur Respir J 2003; 22: 427-435
Year: 2003



Effect of proteinase inhibitor from crataeva tapia (cratabl) in distal lung mechanical, inflammatory and remodeling alterations induced by elastase in mice
Source: Annual Congress 2011 - Anti-inflammatory strategies in acute lung injury
Year: 2011